Prelude Therapeutics, Inc. PRLD 深 沪
等待开盘 05-21 09:30:00 美东时间
4.37
+0.100
+2.34%
华盛通- 最 高4.47
- 今 开4.30
- 成交量 27.73万股
- 最 低 4.12
- 昨 收 4.27
- 总市值 3.48亿
- 52周最高 5.54
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 0.75
- 委 比 -20.26%
- 总股本 7964.53万
- 历史最高 95.375
- 量 比 0.82
- 振 幅 8.20%
- 历史最低 0.6101
- 每 手 1
- 风险率 1.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.25) by 48 percent. This is a 69.05 percent increase over losses of $(0.42) per share from
05-12 19:46
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9
D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Buy rating and announces Price Target of $9.
05-04 21:58
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
Prelude Therapeutics, Inc. ($PRLD) announced an update on their ongoing clinica...
05-03 00:30
美股夜盘 | Prelude Therapeutics, Inc.涨21.78%，最新股价5.2美元
Prelude Therapeutics, Inc.涨21.78%，报5.2美元
05-01 08:21
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday
Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.
04-27 20:40
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8
HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.
04-27 19:57
Prelude Therapeutics prices $90M equity offering
Prelude Therapeutics (PRLD) has priced a public offering of more than 18M shares of its voting common stock at $4.44 each, along with pre-funded warrants for up to 2.25M additional shares at $4.4399 e...
04-20 18:38
Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share
In lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which represents the per share offering price
04-20 18:32
